FDA-approved
Skin & aging
Difelikefalin
Evidence
FDA approved
Class
Kappa opioid receptor agonist peptide
KEY TAKEAWAY
Difelikefalin is a synthetic peptide made of D-amino acids that acts on kappa opioid receptors outside the central nervous system. It is sold as Korsuva. The FDA approved difelikefalin (Korsuva) in August 2021 for itch linked to chronic kidney disease in adults receiving hemodialysis.
Written by the Veylo editorial team · Updated
November 2026
What it is
Kappa opioid receptor agonist peptide
Approved for
Moderate to severe itch in adults with chronic kidney disease on hemodialysis
Key fact
The FDA approved difelikefalin (Korsuva) in August 2021 for itch linked to chronic kidney disease in adults receiving hemodialysis.
Route
Intravenous injection at the end of dialysis
Evidence strength
FDA approved
Difelikefalin is a synthetic peptide made of D-amino acids that acts on kappa opioid receptors outside the central nervous system. It is sold as Korsuva.
By acting on kappa receptors on peripheral nerves and immune cells, it reduces the itch signal without the sedation or addiction risk of opioids that act in the brain.
The FDA approved difelikefalin (Korsuva) in August 2021 for itch linked to chronic kidney disease in adults receiving hemodialysis.
Moderate to severe itch in adults with chronic kidney disease on hemodialysis.
Dizziness, diarrhea, nausea and sleepiness are the most commonly reported effects.
U.S. FDA prescribing information for Difelikefalin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.